Trial
NCT02287727
Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Rectal Adenocarcinoma
Intervention
Laboratory Biomarker Analysis
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-12